Skip to main content
Log in

Das nichtentzugsbedingte Delir

Evidenz zu Prävention und Therapie

Non-withdrawal-related delirium

Evidence on prevention and therapy

  • Übersichten
  • Published:
Der Nervenarzt Aims and scope Submit manuscript

Zusammenfassung

Das Delir ist im klinischen Alltag häufig, aber unterdiagnostiziert. Die Behandlung des oft multifaktoriell bedingten schweren Krankheitsbildes, welches mit hoher Mortalität und immensen Kosten für das Gesundheitssystem einhergeht, erfolgt oft spät und beschränkt sich meist auf pharmakologische Maßnahmen. Wir geben einen Überblick zu Kernsymptomen und Risikofaktoren des Delirs, medikamentösen und nichtmedikamentösen Behandlungsstrategien und Möglichkeiten der Delirprävention.

Abstract

Delirium is a severe and common yet under-diagnosed disorder in the clinical routine. Multiple factors may contribute to the development of delirium, which is associated with increased mortality and high healthcare costs. Treatment of delirium is often provided with delay and limited to pharmacological interventions. This article summarizes the key symptoms for delirium as well as risk factors and highlights the pharmacological and non-pharmacological options for treatment and prevention.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Dilling DMW, Schmidt MH (2011) Internationale Klassifikation psychischer Störungen. ICD-10 Kapitel F0. Klinisch-diagnostische Leitlinien, 8. Aufl. Hogrefe, Bern

    Google Scholar 

  2. Inouye SK, Westendorp RG, Saczynski JS (2014) Delirium in elderly people. Lancet 383(9920):911–922

    Article  PubMed  PubMed Central  Google Scholar 

  3. Hatta K et al (2014) Preventive effects of ramelteon on delirium: a randomized placebo-controlled trial. JAMA Psychiatry 71(4):397–403

    Article  CAS  PubMed  Google Scholar 

  4. Francis J, Young G (2015) Diagnosis of delirium and confusional states. www.uptodate.com. Zugegriffen: 31.03.2015

    Google Scholar 

  5. Hüfner K, Sperner-Unterweger B (2014) Delir in der Neurologie - Diagnose, Behandlung und Prognose. Nervenarzt 85:427–436

    Article  PubMed  Google Scholar 

  6. Rundshagen I (2014) Postoperative kognitive Dysfunktion. Dtsch Arztebl Int 111:119–125

    PubMed  PubMed Central  Google Scholar 

  7. Ahmed S, Leurent B, Sampson EL (2014) Risk factors for incident delirium among older people in acute hospital medical units: a systematic review and meta-analysis. Age Ageing 43(3):326–333

    Article  PubMed  PubMed Central  Google Scholar 

  8. van Meenen LC et al (2014) Risk prediction models for postoperative delirium: a systematic review and meta-analysis. J Am Geriatr Soc 62(12):2383–2390

    Article  PubMed  Google Scholar 

  9. Shi Q et al (2012) Delirium in acute stroke: a systematic review and meta-analysis. Stroke 43(3):645–649

    Article  PubMed  Google Scholar 

  10. Witlox J, Eurelings L, de Jonghe JEA (2010) Delirium in elderly patients and the risk of postdischarge mortality, institutionalization, and dementia: a meta-analysis. JAMA 304:443–451

    Article  CAS  PubMed  Google Scholar 

  11. Mach JR Jr. et al (1995) Serum anticholinergic activity in hospitalized older persons with delirium: a preliminary study. J Am Geriatr Soc 43(5):491–495

    Article  PubMed  Google Scholar 

  12. Campbell N et al (2009) The cognitive impact of anticholinergics: a clinical review. Clin Interv Aging 4:225–233

    PubMed  PubMed Central  Google Scholar 

  13. Trzepacz PT (1994) The neuropathogenesis of delirium. A need to focus our research. Psychosomatics 35(4):374–391

    Article  CAS  PubMed  Google Scholar 

  14. Trzepacz P (2000) Is there a final common neural pathway in delirium? Focus on acetylcholine and dopamine. Semin Clin Neuropsychiatry 5:132–148

    CAS  PubMed  Google Scholar 

  15. Cerejeira J, Lagarto L, Mukaetova-Ladinska EB (2014) The immunology of delirium. Neuroimmunomodulation 21(2–3):72–78

    CAS  PubMed  Google Scholar 

  16. Androsova G et al (2015) Biomarkers of postoperative delirium and cognitive dysfunction. Front Aging Neurosci 7:1–16

    Article  Google Scholar 

  17. Downing J, Miyan J (2000) Neural immunoregulation: emerging roles for nerves in immune homeostasis and disease. Immunol Today 21:281–289

    Article  CAS  PubMed  Google Scholar 

  18. D’Mello C, Le T, Swain M (2009) Cerebral microglia recruit monocytes into the brain in response to tumor necrosis factor-alpha signaling during peripheral organ inflammation. Neuroscience 29(7):2089–2102

    PubMed  Google Scholar 

  19. Steiner LA (2011) Postoperative delirium. Part 1: pathophysiology and risk factors. Eur J Anaesthesiol 28(9):628–636

    Article  CAS  PubMed  Google Scholar 

  20. Cerejeira J et al (2012) The cholinergic system and inflammation: common pathways in delirium pathophysiology. J Am Geriatr Soc 60(4):669–675

    Article  PubMed  Google Scholar 

  21. Tracey K (2009) Reflex control of immunity. Nat Rev Immunol 9:418–428

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Tune L (2002) The role of antipsychotics in treating delirium. Curr Psychiatry Rep 4(3):209–212

    Article  PubMed  Google Scholar 

  23. Inouye SK et al (1990) Clarifying confusion: the confusion assessment method. A new method for detection of delirium. Ann Intern Med 113(12):941–948

    Article  CAS  PubMed  Google Scholar 

  24. Trzepacz PT (1999) The delirium rating scale. its use in consultation-liaison research. Psychosomatics 40(3):193–204

    Article  CAS  PubMed  Google Scholar 

  25. National Institut for Health and Care Excellence (NICE) (2010) Delirium: diagnosis, prevention and management. www.nice.org.uk/CG103. Zugegriffen: 09.09.2015

    Google Scholar 

  26. Wong CL et al (2010) Does this patient have delirium? Value of bedside instruments. JAMA 304:779–786

    Article  CAS  PubMed  Google Scholar 

  27. Lai MM, Wong Tin Niam DM (2012) Intracranial cause of delirium: computed tomography yield and predictive factors. Intern Med J 42(4):422–427

    Article  CAS  PubMed  Google Scholar 

  28. Jacobson S, Jerrier H (2000) EEG in delirium. Semin Clin Neuropsychiatry 5(2):86–92

    CAS  PubMed  Google Scholar 

  29. Jenssen S (2005) Electroencephalogram in the dementia workup. Am J Alzheimers Dis Other Demen 20(3):159–166

    Article  PubMed  Google Scholar 

  30. Rivosecchi RM et al (2015) Nonpharmacological interventions to prevent delirium: an evidence-based systematic review. Crit Care Nurse 35(1):39–50

    Article  PubMed  Google Scholar 

  31. Caplan GA, Harper EL (2007) Recruitment of volunteers to improve vitality in the elderly: the REVIVE study. Intern Med J 37(2):95–100

    Article  CAS  PubMed  Google Scholar 

  32. Colombo R et al (2012) A reorientation strategy for reducing delirium in the critically ill. Results of an interventional study. Minerva Anestesiol 78(9):1026–1033

    CAS  PubMed  Google Scholar 

  33. Tabet N et al (2005) An educational intervention can prevent delirium on acute medical wards. Age Ageing 34(2):152–156

    Article  PubMed  Google Scholar 

  34. Lundstrom M et al (2005) A multifactorial intervention program reduces the duration of delirium, length of hospitalization, and mortality in delirious patients. J Am Geriatr Soc 53(4):622–628

    Article  PubMed  Google Scholar 

  35. de Jonghe A et al (2014) Effect of melatonin on incidence of delirium among patients with hip fracture: a multicentre, double-blind randomized controlled trial. CMAJ 186:E547–E556

    Article  PubMed  PubMed Central  Google Scholar 

  36. Al-Aama T et al (2011) Melatonin decreases delirium in elderly patients: a randomized, placebo-controlled trial. Int J Geriatr Psychiatry 26(7):687–694

    Article  PubMed  Google Scholar 

  37. Chen S et al (2015) Exogenous Melatonin for delirium prevention: a meta-analysis of randomized controlled trials. Mol Neurobiol. doi: 10.1007/s12035-015-9350-8

    Google Scholar 

  38. Kalisvaart KJ et al (2005) Haloperidol prophylaxis for elderly hip-surgery patients at risk for delirium: a randomized placebo-controlled study. J Am Geriatr Soc 53(10):1658–1666

    Article  PubMed  Google Scholar 

  39. Larsen KA et al (2010) Administration of olanzapine to prevent postoperative delirium in elderly joint-replacement patients: a randomized, controlled trial. Psychosomatics 51(5):409–418

    Article  CAS  PubMed  Google Scholar 

  40. Prakanrattana U, Prapaitrakool S (2007) Efficacy of risperidone for prevention of postoperative delirium in cardiac surgery. Anaesth Intensive Care 35(5):714–719

    CAS  PubMed  Google Scholar 

  41. Wang W et al (2012) Haloperidol prophylaxis decreases delirium incidence in elderly patients after noncardiac surgery: a randomized controlled trial. Crit Care Med 40(3):731–739

    Article  PubMed  Google Scholar 

  42. Fok MC et al (2015) Do antipsychotics prevent postoperative delirium? A systematic review and meta-analysis. Int J Geriatr Psychiatry 30(4):333–344

    Article  PubMed  Google Scholar 

  43. Gilmore ML, Wolfe DJ (2013) Antipsychotic prophylaxis in surgical patients modestly decreases delirium incidence – but not duration – in high-incidence samples: a meta-analysis. Gen Hosp Psychiatry 35(4):370–375

    Article  PubMed  Google Scholar 

  44. Ford AH, Almeida OP (2015) Pharmacological interventions for preventing delirium in the elderly. Maturitas 81:287–292

    Article  CAS  PubMed  Google Scholar 

  45. Maust DT et al (2015) Antipsychotics, other Psychotropics, and the risk of death in patients with dementia number needed to harm. JAMA Psychiatry 72:438–445

    Article  PubMed  PubMed Central  Google Scholar 

  46. Frölich L, Hausner L (2015) Therapie mit Antipsychotika und Antidepressiva bei Demenzen. Nervenarzt 86:461–467

    Article  PubMed  Google Scholar 

  47. Lonergan E et al (2007) Antipsychotics for delirium. Cochrane Database Syst Rev 2:CD005594

    PubMed  Google Scholar 

  48. Han CS, Kim YK (2004) A double-blind trial of risperidone and haloperidol for the treatment of delirium. Psychosomatics 45(4):297–301

    Article  CAS  PubMed  Google Scholar 

  49. Hu HDW, Yang H (2004) A prospective random control study comparison of olanzapine and haloperidol in senile delirium. Chongging Med J 8:1234–1237

    Google Scholar 

  50. Skrobik YK1, Bergeron N, Dumont M, Gottfried SB (2004) Olanzapine vs haloperidol: treating delirium in a critical care setting. Intensive Care Med 30(3):444–449

    Article  PubMed  Google Scholar 

  51. Tahir TA et al (2010) A randomized controlled trial of quetiapine versus placebo in the treatment of delirium. J Psychosom Res 69(5):485–490

    Article  PubMed  Google Scholar 

  52. Devlin JW et al (2010) Efficacy and safety of quetiapine in critically ill patients with delirium: a prospective, multicenter, randomized, double-blind, placebo-controlled pilot study. Crit Care Med 38(2):419–427

    Article  CAS  PubMed  Google Scholar 

  53. Maneeton B et al (2013) Quetiapine versus haloperidol in the treatment of delirium: a double-blind, randomized, controlled trial. Drug Des Devel Ther 7:657–667

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  54. Tanimukai H et al (2014) Novel therapeutic strategies for delirium in patients with cancer: a preliminary study. Am J Hosp Palliat Care. doi:10.1177/1049909II4565019. (Epub ahead of print)

    PubMed  Google Scholar 

  55. Kirino E (2015) Use of aripiprazole for delirium in the elderly: a short review. Psychogeriatrics 15(1):75–84

    Article  PubMed  Google Scholar 

  56. Hale GM et al (2015) An evaluation of adverse drug reactions associated with Antipsychotic use for the treatment of delirium in the intensive care unit. J Pharm Pract. doi:10.1177/0897190014566313. (Epub ahead of print)

    PubMed  Google Scholar 

  57. Lonergan E et al (2009) Benzodiazepines for delirium. Cochrane Database Syst Rev 1:CD006379

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to R. Haussmann.

Ethics declarations

Interessenkonflikt

R. Haussmann gibt an, dass kein Interessenkonflikt besteht. M. Donix: Forschungsförderung durch die Roland Ernst Stiftung und ein Beraterhonorar von Trommsdorff. M. Bauer: Forschungszuwendungen: Deutsche Forschungsgemeinschaft (DFG), Bundesministerium für Bildung und Forschung (BMBF), American Foundation of Suicide Prevention. Beratertätigkeit: AstraZeneca, BristolMyers Squibb, Ferrer Internacional, Merz, Novartis, Janssen, Lilly, Lundbeck, Otsuka, Servier, Takeda. Vortragshonorare: AstraZeneca, Pfizer, Lilly, Lundbeck, Otsuka, Servier.

Dieser Beitrag beinhaltet keine Studien an Menschen oder Tieren.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Haussmann, R., Bauer, M. & Donix, M. Das nichtentzugsbedingte Delir. Nervenarzt 87, 534–542 (2016). https://doi.org/10.1007/s00115-015-0027-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00115-015-0027-3

Schlüsselwörter

Keywords

Navigation